Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the fourth quarter of 2025.
…
Vis børsmeldingen
Highlights include:
Record sales of NOK 46.6 million in 4Q25, up 9% vs 4Q24 (12% organic growth). Full year 2025 sales of NOK 176.5 million up 16% (17% organic growth) vs 2024.
EBITDA of NOK 10.5 million in 4Q25 vs NOK 8.1 million in 4Q24. For the full year of 2025 the EBITDA was NOK 34.6 million vs 24.7 million in 2024 (+40%). The EBITDA for 2025 includes NOK 13.3 million (NOK 12 million) in pipeline development expenses.
Improved gross margin to 58% (56%) in 4Q25 and to 56% in 2025 versus 54% in 2024.
Sales of Cystatin C increased with 22% in 4Q25 compared to 4Q24, and by 32% for the full year 2025 versus 2024, driven by strong performance in the US.
Sales of fCAL turbo decreased with 6% in 4Q25 compared to 4Q24, and by 1% for the full year 2025 versus 2024, due to unusual high stock building in 4Q24.
Sales to the US were NOK 29.4 million in 2025 vs NOK 12.2 million in 2024. New accounts and growth in existing accounts both contributed to increased revenues. The warehouse shift for one of our largest customers accounts for about NOK 11.3 million of the 2025 revenue.
Very recent testing shows that the current assay version of NT-proBNP does not perform reliably in the lower measurement range. The company has therefore initiated activities to investigate whether redesigning the assay could improve robustness, with initial results to be shared once available. The company expects to present revised development timelines during Q2 2026.
Gentian announced an exclusive partnership with a top global diagnostics company to develop a new assay that will be incorporated into one of the world’s most widely used clinical chemistry analyser platforms.
The board proposes a dividend of NOK 0.60 per share based on a solid cash position and sound underlying earnings with current growth opportunities fully financed.
Webcast
The company will present the results today at 09.00 am, followed by a Q&A session. The presentation will be held as a live webcast on the company’s website:
Gentian Diagnostic - Investor presentations
The webcast will also be available on the company website after the presentation.
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Ole Sørlie, Business controller at Gentian Diagnostics ASA, on 11 February 2025 at 08:20 CET.
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lie within immunoassays, specifically for infections, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.
Kilde
